Berlex' Yaz Launch To Proceed Despite Patent Suit
This article was originally published in The Pink Sheet Daily
Executive Summary
Warner Chilcott files suit against Berlex alleging Yaz infringes a patent covering Warner’s contraceptive Loestrin 24 Fe.
You may also be interested in...
Berlex’ Yaz Gains Indication For Premenstrual Dysphoric Disorder
The oral contraceptive is the first approved for the treatment of emotional and physical symptoms of PMDD.
Berlex’ Yaz Gains Indication For Premenstrual Dysphoric Disorder
The oral contraceptive is the first approved for the treatment of emotional and physical symptoms of PMDD.
Berlex’ YAZ Clears FDA For Contraception; April Launch Planned
A premenstrual dysphoric disorder indication for the low-dose version of Yasmin is still pending.